Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor
XTalks
FEBRUARY 27, 2024
Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.” TILs can spot tumor antigens derived from intra- or extracellular tumor proteins in the tumor microenvironment. With growing interest in TIL therapies, investors have invested $2.7
52 
Let's personalize your content